Arsanis Inc (NASDAQ:ASNS) has received an average recommendation of “Hold” from the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $14.25.
Several research firms have weighed in on ASNS. Zacks Investment Research lowered shares of Arsanis from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 14th. ValuEngine upgraded shares of Arsanis from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Piper Jaffray Companies dropped their price objective on shares of Arsanis to $2.50 and set a “neutral” rating on the stock in a research note on Monday, August 13th.
Institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System acquired a new position in shares of Arsanis during the 1st quarter worth $162,000. Alambic Investment Management L.P. increased its stake in shares of Arsanis by 1,004.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 133,661 shares of the company’s stock worth $217,000 after purchasing an additional 121,561 shares during the last quarter. Granahan Investment Management Inc. MA acquired a new position in shares of Arsanis during the 2nd quarter worth $365,000. Northern Trust Corp acquired a new position in shares of Arsanis during the 1st quarter worth $735,000. Finally, BlackRock Inc. increased its stake in shares of Arsanis by 27.1% during the 2nd quarter. BlackRock Inc. now owns 223,797 shares of the company’s stock worth $812,000 after purchasing an additional 47,777 shares during the last quarter. Hedge funds and other institutional investors own 63.38% of the company’s stock.
Arsanis (NASDAQ:ASNS) last released its quarterly earnings data on Friday, November 9th. The company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.02). Equities research analysts forecast that Arsanis will post -2.97 earnings per share for the current year.
Arsanis Company Profile
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Featured Article: What is the Rule of 72?
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.